JP2024529307A - 線維芽細胞活性化タンパク質（ｆａｐ）に結合する放射性トレーサーおよび治療薬 - Google Patents

線維芽細胞活性化タンパク質（ｆａｐ）に結合する放射性トレーサーおよび治療薬 Download PDF

Info

Publication number
JP2024529307A
JP2024529307A JP2024500469A JP2024500469A JP2024529307A JP 2024529307 A JP2024529307 A JP 2024529307A JP 2024500469 A JP2024500469 A JP 2024500469A JP 2024500469 A JP2024500469 A JP 2024500469A JP 2024529307 A JP2024529307 A JP 2024529307A
Authority
JP
Japan
Prior art keywords
conjugate
fap
acid
sifa
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024500469A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024529307A5 (enExample
Inventor
ラーマン，サビター
ベジョー，ロマン
リャン，グヤン
ハジ，アブドゥル・カリム
バーネス，コリン
Original Assignee
ブルー アース ダイアグノスティックス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブルー アース ダイアグノスティックス リミテッド filed Critical ブルー アース ダイアグノスティックス リミテッド
Publication of JP2024529307A publication Critical patent/JP2024529307A/ja
Publication of JP2024529307A5 publication Critical patent/JP2024529307A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0472—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2024500469A 2021-07-09 2022-07-08 線維芽細胞活性化タンパク質（ｆａｐ）に結合する放射性トレーサーおよび治療薬 Pending JP2024529307A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2109922.1 2021-07-09
GBGB2109922.1A GB202109922D0 (en) 2021-07-09 2021-07-09 Radiotracers and therapeutics binding to fibroblast activation protein (fap)
PCT/US2022/073544 WO2023283627A1 (en) 2021-07-09 2022-07-08 Radiotracers and therapeutics binding to fibroblast activation protein (fap)

Publications (2)

Publication Number Publication Date
JP2024529307A true JP2024529307A (ja) 2024-08-06
JP2024529307A5 JP2024529307A5 (enExample) 2025-06-11

Family

ID=77353994

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024500469A Pending JP2024529307A (ja) 2021-07-09 2022-07-08 線維芽細胞活性化タンパク質（ｆａｐ）に結合する放射性トレーサーおよび治療薬

Country Status (7)

Country Link
US (1) US20240399001A1 (enExample)
EP (1) EP4366786A1 (enExample)
JP (1) JP2024529307A (enExample)
KR (1) KR20240035488A (enExample)
CN (1) CN117836013A (enExample)
GB (1) GB202109922D0 (enExample)
WO (1) WO2023283627A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118804921A (zh) * 2023-01-17 2024-10-18 云合智药（苏州）生物科技有限公司 缀合物、配体单元及其用途
WO2024227137A1 (en) * 2023-04-28 2024-10-31 The Board Of Regents Of The University Of Texas System Structurally-reinforced stable theranostic copper radiopharmaceuticals targeting fibroblast activation protein for cancer diagnosis and therapy
AU2024381248A1 (en) * 2023-11-16 2026-06-11 Praxis Biotech LLC Conjugates targeting fibroblast activation protein and uses thereof
WO2026041109A1 (zh) * 2024-08-23 2026-02-26 苏州博锐创合医药有限公司 成纤维细胞活化蛋白抑制剂及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7162592B2 (ja) 2016-12-14 2022-10-28 パーデュー・リサーチ・ファウンデイション 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療
KR20240027896A (ko) 2017-07-28 2024-03-04 테크니쉐 우니베르지테트 뮌헨 이중 모드 방사성 트레이서 및 치료법
JP2021500373A (ja) 2017-10-23 2021-01-07 ザ・ジョンズ・ホプキンス・ユニバーシティ 線維芽細胞活性化タンパク質α（ＦＡＰ−α）を標的とする撮像剤および放射線療法用薬剤
PH12020551205A1 (en) 2018-02-06 2021-04-19 Univ Heidelberg Fap inhibitors
CA3128406A1 (en) 2019-01-30 2020-08-06 Technische Universitat Munchen Cancer diagnostic imaging agents
WO2020157177A1 (en) 2019-01-30 2020-08-06 Technische Universität München Psma binding dual mode radiotracer and therapeutic
PL3997103T3 (pl) 2019-07-08 2025-03-24 3B Pharmaceuticals Gmbh Związki zawierające ligand białka aktywującego fibroblasty i ich zastosowanie
CN118955620A (zh) 2019-07-08 2024-11-15 3B制药有限公司 包含成纤维细胞活化蛋白配体的化合物及其用途

Also Published As

Publication number Publication date
EP4366786A1 (en) 2024-05-15
US20240399001A1 (en) 2024-12-05
GB202109922D0 (en) 2021-08-25
CN117836013A (zh) 2024-04-05
WO2023283627A9 (en) 2023-03-02
KR20240035488A (ko) 2024-03-15
WO2023283627A1 (en) 2023-01-12

Similar Documents

Publication Publication Date Title
US20240399001A1 (en) Radiotracers and therapeutics binding to fibroblast activation protein (fap)
JP7653082B2 (ja) スクアリン酸カップリングを有する標識前駆体
AU2019225154B2 (en) Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer
JP7515023B2 (ja) 二重標的化化合物及びその調製方法と応用
CN108541302B (zh) 用于成像和治疗的尿素基前列腺特异性膜抗原(psma)抑制剂
AU2019356168B9 (en) Imaging agents
ES2990974T3 (es) Conjugados de folato de entidades fijadoras de albúmina
BR112020001785A2 (pt) radiotraçador e compostos radioterapêuticos bimodais
CN115505032B (zh) 一种成纤维细胞活化蛋白FAP和整合素αvβ3双重靶向化合物及其制备方法和应用
ES2281927T3 (es) Complejantes tetraaza- o n2s2-, y su uso en radiodiagnostico o en radioterapia.
KR20230118160A (ko) 섬유아세포 활성화 단백질 억제제
JP7213493B2 (ja) ニューロテンシン受容体関連病態の診断、治療及び予防
TW202241527A (zh) 雙模放射性追蹤劑及治療方法
CN115010629A (zh) 前列腺特异性膜抗原抑制剂、其核素标记物及制法和应用
WO2025218677A1 (zh) 双重靶向成纤维细胞激活蛋白和整合素亚型的化合物及其制备和应用
JP2026508513A (ja) 窒素含有複素環系化合物およびその製造方法と使用
JP7771080B2 (ja) 医薬配合物
CN117279930A (zh) 三官能化合物和其用途
JP2024507343A (ja) デュアルモード放射性トレーサーおよびその療法
Singh et al. A homodimeric bivalent radioligand derived from 1-(2-methoxyphenyl) piperazine with high affinity for in vivo 5-HT1A receptor imaging
CN121909051A (zh) 靶向成纤维细胞活化蛋白的组合物及其使用方法
JP2025540658A (ja) 神経ペプチドｙ１受容体（ｎｐｙ１ｒ）を標的とした治療薬およびその使用
CN120590466B (zh) 一种靶向成纤维细胞活化蛋白的化合物及其应用
WO2024037635A1 (en) A trifunctional compound and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250603

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260806